Clinical Trials Browser

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT06528691 2026-03-23

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04603807 2026-02-27

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Phase 3 Active not recruiting

220 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05770544 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicLymphoidOther hematologic neoplasm

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT05396859 2025-10-20

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1 Active not recruiting

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07199959 2025-09-30

Study on the Mechanism of Acquired Resistance of Entrectinib

Recruiting

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT05525858 2025-04-27

KOSMOSII

Recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT04551495 2024-12-04

ROSALINE

Phase 2 Active not recruiting

65 enrolled

Carcinoma, Lobular

NCT06694129 2024-11-19

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04817956 2024-02-29